iRhythm Technologies Receives European Approval for Advanced Zio Wearable Cardiac Monitor

iRhythm Technologies, a leading player in the field of cardiac monitoring, has recently obtained approval from European regulatory authorities for its latest Zio wearable cardiac monitor. This cutting-edge device is specifically designed to enhance the detection of hidden irregular heartbeats, including conditions like atrial fibrillation, providing a significant advancement in the realm of cardiovascular health.

The newly approved model boasts a remarkable reduction in size, thickness, and weight compared to iRhythm's previous Zio XT ECG-recording patch, underscoring the company's commitment to advancing technology for patient convenience. Cases of arrhythmia and stroke have been on the rise in Europe, prompting the need for more effective detection methods. The green light from the CE mark covers both the 14-day Zio wearable monitor and its innovative artificial intelligence-powered ECG analysis software known as ZEUS.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

Quentin Blackford, President and CEO of the company, commended the company's teams for effectively conveying the substantial body of clinical study evidence supporting the Zio services and the deep-learned AI algorithm as key differentiators. Blackford expressed anticipation for introducing this innovative technology to a broader patient population in Europe, emphasizing the improved clinical accuracy compared to traditional Holter monitoring.

The company plans to further expand its commercial reach in selected European countries, recognizing the demand for enhanced cardiac monitoring. In Europe, where approximately 1.8 million cardiac monitoring tests are conducted annually, the introduction of the advanced Zio monitor is expected to contribute significantly to improved patient outcomes.

The Zio wearable monitor made its debut in the United States in September, with studies showcasing an impressive 99% patient compliance rate. Participants demonstrated adherence by wearing the device throughout their prescribed duration, and the device's user-friendly features include no need for recharging, breathable adhesives, and a waterproof sensor housing.

Financially, iRhythm reported $124.6 million in revenue for the third quarter of 2023, marking a 20% gain over the corresponding period in the previous year. Looking forward, the company's full-year sales growth projection of approximately 19% anticipates total revenues ranging between $487.5 million and $490 million, showcasing confidence in the continued success and market penetration of their innovative cardiac monitoring solutions.